The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by rejecting AstraZeneca’s PT010, a close competitor. AZ has confirmed ...

Objective: To review the basis for the estimated comparative daily dosages of inhaled corticosteroids for children and adults that are presented in the National Heart, Lung, and Blood Institute's ...

Correspondence to Dr Sharon Conroy, Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Uttoxeter Road, Derby DE22 3DT, ...